| Open | 45.02 |
| Previous Close | 43.64 |
| Volume | 959.4 Thou. |
| Average Volume | 954.5 Thou. |
| Day's Range | 43.95 โ 45.45 |
| 52 Week Range | 19.445-53.27 |
| Market Cap | 2.89 Bil. |
| Moving Average (50) | 36.9612 |
| Moving Average (200) | 39.44503 |
| Earnings per Share (EPS) | -3.11 |
| Price/Earnings (PE) | -14.29 |
| Shares Outstanding | 65.12 Mil. |
| Earnings Date | Aug 05, 2025 |
| Beta | 2.074 |
| Last Dividend | 0 |
KYMR Latest News
|
|
|
|
|
|
|
|
|
|
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| About Kymera Therapeutics | |
| Industry | Biotechnology |
| Sector | Healthcare |
| Number of Employees | 208 |
| Website & Executive | |
| Website | https://www.kymeratx.com |
| CEO (Chief Executive Officer) | Nello Mainolfi |
| IPO date | 2020-08-21 |
| Contact | |
| Country | US |
| Address | 200 Arsenal Yards Boulevard |
| City | Watertown |
| State | MA |
| Phone | 857 285 5300 |
| Zip Code | 02472 |
| Other Identifiers | |
| CIK | 0001815442 |
| ISIN | US5015751044 |
| CUSIP | 501575104 |
